💖 CorDx Tumour & Cardiac Marker Tests: Critical Insights for Oncology and Cardiology CorDx provides a focused portfolio of rapid diagnostic tests for critical Tumour and Cardiac Markers, enabling timely intervention and management across oncology and cardiology. By applying our vertically integrated supply chain, we deliver diagnostics that meet the rigorous demands of global clinical practice.
🔬 The Precision of Diagnostic Biomarkers
Our tests utilise Lateral Flow Immunoassay (LFIA) technology in convenient Cassette or Multi-Panel formats to detect specific protein biomarkers in Serum, Plasma, Whole Blood, or Feces. These markers are crucial for risk stratification, diagnosis, monitoring treatment efficacy, and surveillance in high-burden disease areas:
Cardiac Markers (Troponin, Myoglobin, CK-MB): The Troponin (cTnI) Test and the Cardiac Marker Multi-Panel (cTnI/MYO/CK-MB) Test are designed to detect markers of myocardial injury. Troponin, in particular, is the gold standard for diagnosing acute coronary syndromes (ACS). Providing these results rapidly is essential for managing time-sensitive cardiac events.
Tumor Markers (PSA, CEA, FOB):
Prostate Specific Antigen (PSA) Test: Detects elevated levels of PSA in Serum/Plasma/Whole Blood, a key biomarker used in the screening and monitoring of prostate cancer.
Carcinoembryonic Ag (CEA) Test: Detects CEA, a marker often elevated in various epithelial cancers, used for monitoring disease recurrence and treatment response.
Fecal Occult Blood (FOB) Test: Detects hidden blood in the stool, serving as a non-invasive screening tool for colorectal cancer and other gastrointestinal conditions.
Our tests are formulated for high sensitivity (e.g., 2ng/ml for Troponin and 4ng/ml for PSA), ensuring detection at clinically relevant thresholds.
🏭 CorDx’s Integrated System: Ensuring Global Access to Critical Care
The ability to deploy these life-saving diagnostics globally is powered by our vertically integrated supply chain. CorDx controls the entire manufacturing process, from raw materials (antibodies, plastic cassettes) to the final regulated product. This model ensures:
Reliable Availability: Eliminates supply chain bottlenecks, guaranteeing that hospitals and clinics worldwide—especially those in remote or resource-limited settings—have uninterrupted access to these time-critical diagnostic tools.
Affordable Cost: By driving manufacturing efficiency, we provide cost-effective solutions that support widespread adoption in population-based screening programs (like FOB) and continuous cardiac monitoring.
Quality Assurance: Every production stage operates under strict GMP and ISO Certified Quality Management Systems, ensuring the highest standards of accuracy and performance demanded by oncology and cardiology specialists.
✅ Regulatory Validation for Clinical Confidence
Our commitment to quality is confirmed by global regulatory clearances, giving clinical partners the confidence to integrate our tests into their patient management protocols:
CE Mark: All products in this category, including the Cardiac Marker Multi-Panel and FOB Tests, are registered with the CE Mark (0197,CE), signifying compliance with the European Union’s health, safety, and environmental protection standards.
Global Compliance: This level of regulatory compliance facilitates streamlined distribution and market entry, enabling CorDx to rapidly support healthcare systems across Europe and other global territories reliant on CE certification.
By providing high-quality, accessible, and reliably supplied diagnostics for key tumour and cardiac markers, CorDx empowers healthcare providers to make timely, informed decisions that improve patient outcomes in the fight against major chronic and acute diseases.